{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:29:45Z","timestamp":1787621385759,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtha.2024.12.035","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:00:53Z","timestamp":1736424053000},"page":"1315-1331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatment"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-3035","authenticated-orcid":false,"given":"Marisol","family":"Betensky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Biss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhmi V.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R.","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Diacovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Raffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Revel-vilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Heleen","family":"van Ommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.12.035_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2017.11.019","article-title":"A\u00a0multi-institutional registry of pediatric hospital-acquired thrombosis cases: the Children's Hospital-Acquired Thrombosis (CHAT) project","volume":"161","author":"Jaffray","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.12.035_bib4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1542\/peds.2008-2052","article-title":"Unfractionated heparin therapy in infants and children","volume":"123","author":"Newall","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2024.12.035_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2010.08225.x","article-title":"Aspects of anticoagulation in children","volume":"150","author":"Payne","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.12.035_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.860369","article-title":"Practical considerations for use of direct oral anticoagulants in children","volume":"10","author":"Whitworth","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jtha.2024.12.035_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.12.035_bib8","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.12.035_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/rth2.12352","article-title":"The edoxaban Hokusai VTE PEDIATRICS study: an open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease","volume":"4","author":"van Ommen","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib10","doi-asserted-by":"crossref","first-page":"e021765","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2024.12.035_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brand\u00e3o","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.035_bib12","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.12.035_bib13","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O'Brien","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.12.035_bib14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"Portman","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.12.035_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/rth2.12086","article-title":"Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism","volume":"2","author":"Albisetti","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12959-018-0188-y","article-title":"Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study","volume":"16","author":"Lensing","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2024.12.035_bib17","article-title":"Apixaban for the acute treatment of venous\u00a0thromboembolism in children","author":"gov","year":"2024","journal-title":"ClinicalTrials.gov identifier: NCT02464969"},{"key":"10.1016\/j.jtha.2024.12.035_bib19","author":"gov"},{"key":"10.1016\/j.jtha.2024.12.035_bib20","article-title":"Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE)","author":"gov","year":"2020","journal-title":"ClinicalTrials.gov identifier: NCT01895777"},{"key":"10.1016\/j.jtha.2024.12.035_bib21","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1067\/mpd.2001.118192","article-title":"Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands","volume":"139","author":"van Ommen","year":"2001","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jtha.2024.12.035_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jpeds.2013.10.025","article-title":"Hospital-associated venous thromboembolism in children: incidence and clinical characteristics","volume":"164","author":"Takemoto","year":"2014","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jtha.2024.12.035_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.09.016","article-title":"Development of a risk model for pediatric hospital-acquired thrombosis: a report from the Children\u2019s Hospital-Acquired Thrombosis Consortium","volume":"228","author":"Jaffray","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jtha.2024.12.035_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2005.05.020","article-title":"Difficulties in performing clinical trials of antithrombotic therapy in neonates and children","volume":"118","author":"Massicotte","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.12.035_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100140","article-title":"What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?","volume":"7","author":"Betensky","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib29","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.jtha.2023.07.011","article-title":"Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis","volume":"21","author":"Giossi","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib30","article-title":"The continued rise of venous thromboembolism across US children's hospitals","volume":"149","author":"O'Brien","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2024.12.035_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtha.2022.11.031","article-title":"High rate of recurrent venous thromboembolism in children and adolescents with unprovoked venous thromboembolism","volume":"21","author":"Whitworth","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.035_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1203\/00006450-200006000-00013","article-title":"Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry","volume":"47","author":"Monagle","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jtha.2024.12.035_bib33","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtha.2023.03.004","article-title":"Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis","volume":"21","author":"Whitworth","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:30:44Z","timestamp":1775010644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624007906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1538783624007906"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.035","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}